Sibrotuzumab is a humanized monoclonal antibody intended for the treatment of cancer.

It binds to FAP[1][2] In 2003 it failed a phase II clinical trial for metastatic colorectal cancer.

[3] This monoclonal antibody–related article is a stub.

You can help Wikipedia by expanding it.This antineoplastic or immunomodulatory drug article is a stub.

You can help Wikipedia by expanding it.